Orthopediatrics (NASDAQ:KIDS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The firm currently has a $37.00 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 5.68% from the company’s current price.
According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “
Several other brokerages also recently issued reports on KIDS. BidaskClub downgraded shares of Orthopediatrics from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Needham & Company LLC began coverage on shares of Orthopediatrics in a research note on Wednesday, June 19th. They issued a “buy” rating and a $53.00 target price on the stock. Finally, ValuEngine downgraded shares of Orthopediatrics from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $44.50.
Orthopediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.05). The business had revenue of $18.20 million during the quarter, compared to analysts’ expectations of $18.44 million. Orthopediatrics had a negative return on equity of 12.92% and a negative net margin of 15.77%. Orthopediatrics’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.21) EPS. As a group, equities analysts expect that Orthopediatrics will post -0.82 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of KIDS. Riverbridge Partners LLC lifted its stake in shares of Orthopediatrics by 41.3% in the third quarter. Riverbridge Partners LLC now owns 513,070 shares of the company’s stock worth $18,091,000 after buying an additional 149,855 shares in the last quarter. Roubaix Capital LLC bought a new position in shares of Orthopediatrics in the second quarter worth approximately $3,497,000. BlackRock Inc. lifted its position in Orthopediatrics by 16.8% during the second quarter. BlackRock Inc. now owns 585,555 shares of the company’s stock valued at $22,837,000 after purchasing an additional 84,205 shares during the period. Wasatch Advisors Inc. lifted its position in Orthopediatrics by 28.2% during the second quarter. Wasatch Advisors Inc. now owns 347,598 shares of the company’s stock valued at $13,556,000 after purchasing an additional 76,534 shares during the period. Finally, Calamos Advisors LLC bought a new position in Orthopediatrics during the second quarter valued at approximately $2,373,000. Hedge funds and other institutional investors own 48.16% of the company’s stock.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Recommended Story: What does an inverted yield curve signify?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.